Invivyd (NASDAQ:IVVD) Given “Buy” Rating at BTIG Research

Invivyd (NASDAQ:IVVD)‘s stock had its “buy” rating reissued by research analysts at BTIG Research in a report issued on Tuesday,Benzinga reports. They currently have a $10.00 target price on the stock.

Several other research firms have also recently weighed in on IVVD. HC Wainwright reiterated a “buy” rating on shares of Invivyd in a report on Thursday, May 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Invivyd in a report on Wednesday, April 29th. Finally, Wall Street Zen cut shares of Invivyd from a “hold” rating to a “strong sell” rating in a report on Saturday, May 16th. Three analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Invivyd presently has a consensus rating of “Hold” and an average target price of $8.00.

Invivyd Price Performance

Shares of Invivyd stock traded down $0.03 on Tuesday, hitting $1.00. The company had a trading volume of 3,603,589 shares, compared to its average volume of 2,989,217. The firm has a market capitalization of $293.13 million, a P/E ratio of -3.19 and a beta of 0.63. Invivyd has a twelve month low of $0.48 and a twelve month high of $3.07. The stock has a 50-day moving average of $1.35 and a 200-day moving average of $1.81.

Invivyd (NASDAQ:IVVD) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.05). The company had revenue of $13.74 million during the quarter, compared to analyst estimates of $18.04 million. Invivyd had a negative net margin of 138.90% and a negative return on equity of 53.48%. Equities analysts predict that Invivyd will post -0.5 EPS for the current year.

Institutional Trading of Invivyd

Institutional investors have recently made changes to their positions in the business. Courier Capital LLC bought a new stake in shares of Invivyd in the fourth quarter worth $25,000. Chicago Partners Investment Group LLC bought a new stake in shares of Invivyd in the first quarter worth $25,000. Bronte Capital Management Pty Ltd. bought a new stake in shares of Invivyd in the fourth quarter worth $27,000. DRW Securities LLC bought a new stake in shares of Invivyd in the fourth quarter worth $27,000. Finally, ProShare Advisors LLC bought a new stake in Invivyd during the fourth quarter worth $30,000. Institutional investors own 70.36% of the company’s stock.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.